TOP NEWS: AstraZeneca hails survival rates of breast cancer drugs
(Alliance News) - AstraZeneca PLC on Wednesday said its breast cancer drugs capivasertib and camizestrant significantly improved progression-free survival in a phase 3 and 2 trial respectively. Read More